ATLANTA — This weekend’s American Society of Hematology (ASH) annual meeting was bit like playing in a Brooklyn children’s soccer tournament: Everyone got a congratulatory trophy just for showing up.
Well … not everyone. To extend the tortured P.C. soccer metaphor, Syros Pharmaceuticals (SYRS) was ejected with a red card. Unsportsmanlike conduct.
Its stock was cut in half in early trading because its lead drug, SY-1425, emerged from a weekend presentation looking inert. There was only a single complete bone marrow response among 58 patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
About the Author Reprints
